Object The lateral transpsoas approach for lumbar interbody fusion is a minimal access technique that has been used by some to treat lumbar degenerative conditions, including degenerative scoliosis. Few studies, however, have analyzed its effect on coronal and sagittal plane correction, and no study has compared changes in segmental, regional, and global coronal and sagittal alignment after this technique. The object of this study was to determine changes in sagittal and coronal plane alignment occurring after direct lateral interbody fusion (DLIF). Methods The authors performed a review of the radiographic records of 36 patients with lumbar degenerative disease treated with the DLIF technique. Thirty-five patients underwent supplemental posterior fixation to maintain correction. Preoperative and postoperative standing anteroposterior and lateral lumbar radiographs were obtained in all patients for measurement of segmental and regional coronal and sagittal Cobb angles. Standing anteroposterior and lateral 36-in radiographs were also obtained in 23 patients for measurement of global coronal (center sacral vertebral line) and sagittal (C-7 plumb line) balance. Results The mean coronal segmental Cobb angle was 4.5° preoperatively, and it was 1.5° postoperatively (p < 0.0001). The mean pre- and postoperative regional lumbar coronal Cobb angles were 7.6° and 3.6°, respectively (p = 0.0001). In 8 patients with degenerative scoliosis, the mean pre- and postoperative regional lumbar coronal Cobb angles were 21.4° and 9.7°, respectively (p = 0.0004). The mean global coronal alignment was 19.1 mm preoperatively, and it was 12.5 mm postoperatively (p < 0.05). In the sagittal plane, the mean segmental Cobb angle measured −5.3° preoperatively and −8.2° postoperatively (p < 0.0001). The mean pre- and postoperative regional lumbar lordoses were 42.1° and 46.2°, respectively (p > 0.05). The mean global sagittal alignment was 41.5 mm preoperatively and 42.4 mm postoperatively (p = 0.7). The average clinical follow-up was 21 months in 21 patients. The mean pre- and postoperative visual analog scale scores were 7.7 and 2.9, respectively (p < 0.0001). The mean pre- and postoperative Oswestry Disability Indices were 43 and 21, respectively (p < 0.0001). Conclusions Direct lateral interbody fusion significantly improves segmental, regional, and global coronal plane alignment in patients with degenerative lumbar disease. Although DLIF increases the segmental sagittal Cobb angle at the level of instrumentation, it does not improve regional lumbar lordosis or global sagittal alignment.

Object Recently, the minimally invasive, lateral retroperitoneal, transpsoas approach to the thoracolumbar spinal column has been described by various authors. This is known as the minimally invasive lateral lumbar interbody fusion. The purpose of this study is to elucidate the approach-related morbidity associated with the minimally invasive transpsoas approach to the lumbar spine. To date, there have been only a couple of reports regarding the morbidity of the transpsoas muscle approach. Methods A nonrandomized, prospective study utilizing a self-reported patient questionnaire was conducted between January 2006 and June 2008 at Northwestern University. Data were collected in 53 patients with a follow-up period ranging from 6 months to 3.5 years. Only 2 patients were lost to follow-up. Results Thirty-six percent (19 of 53) of patients reported subjective hip flexor weakness, 25% (13 of 53) anterior thigh numbness, and 23% (12 of 53) anterior thigh pain. However, 84% of the 19 patients reported complete resolution of their subjective hip flexor weakness by 6 months, and most experienced improved strength by 8 weeks. Of those reporting anterior thigh numbness and pain, 69% and 75% improved to their baseline function by the 6-month follow-up evaluations, respectively. All patients with self-reported subjective hip flexor weakness underwent examinations during subsequent clinic visits after surgery; however, these examinations did not confirm a motor deficit less than Grade 5. Subset analysis showed that the L3–4 and L4–5 levels were most often affected. Conclusions The minimally invasive, transpsoas muscle approach to the lumbar spine has a number of advantages. The data show that a percentage of the patients undergoing the transpsoas approach will have temporary sensory and motor symptoms related to this approach. The majority of the symptoms are thought to be related to psoas muscle inflammation and/or stretch injury to the genitofemoral nerve due to the surgical corridor traversed during the operation. No major injuries to the lumbar plexus were encountered. It is important to educate patients prior to surgery of the possibility of these largely transient symptoms.

BACKGROUNDGemcitabine is a commonly used chemotherapeutic agent structurally and pharmacologically similar to cytarabine. Recently, instances of severe gemcitabine‐associated lung injury have been reported. Herein, investigators affiliated with the Research on Adverse Drug Events and Reports (RADAR) pharmacovigilance program evaluated clinical characteristics of gemcitabine‐associated severe acute lung injury from clinical trial reports, medical literature case reports, and spontaneous reports to the Food and Drug Administration (FDA) Adverse Event Reporting System (AERS).METHODSClinical data were obtained by reviewing adverse event case reports for gemcitabine‐associated lung injury as reported in the medical literature and in the FDA AERS database. Upper limit estimates of ADE rate were derived from review of published clinical trials reporting gemcitabine‐associated lung injury rates of 10% or higher.RESULTSA total of 178 reports of gencitabine‐associated lung injury were identified; in AERS, there were 55 cases from clinical trials and 92 spontaneous reports. A comprehensive search revealed 31 medical literature reports. Clinical features of gemcitabine‐associated lung injury included dyspnea, fever, pulmonary infiltrate, and cough with recognition of toxicity occurring after a median duration of 48 (range, 1‐529) days after initiation of gemcitabine. The taxanes, docetaxel and paclitaxel, were frequently reported as coadministered therapies. Eleven Phase II or Phase III clinical trials with 317 patients identified gemcitabine‐associated lung injury rates of greater than 10%, with the highest rates (22% and 42%) being observed in Phase III clinical trials where Hodgkin disease patients were treated with a regimen that included gemcitabine and bleomycin.CONCLUSIONSHigh rates of gemcitabine‐associated severe lung injury were observed when gemcitabine was combined with other therapies known to also cause lung injury. Physicians should have a high index of suspicion for this toxicity and report the relevant clinical findings to the FDA's AERS. Cancer 2006. © 2006 American Cancer Society.